129.65
-0.71 (-0.54%)
KOPRAN • 17 Dec, 2025 | 03:29 PM
Kopran Stock Performance
|
|
|
Kopran Company background
Founded in: 1958
Kopran Limited, incorporated on April 26, 1958, was promoted by the Somani group and is a group company of Parijat Enterprises. Company operates in two distinct business verticals. While pharmaceutical formulations production is managed by Kopran Limited, manufacturing of API is operated under Kopran Research Laboratories Limited (KRLL). Company specialise in developing and manufacturing Penicillin and nonpenicillinbased drugs. Leveraging cuttingedge technology, it manufactures highquality finished dosage drugs that adhere to international requirements. Kopran is one of the key contributors in the manufacturing and sale of diverse active pharmaceutical ingredients and advanced intermediates. The range of APIs manufactured by the Company includes Sterile Cephalosporins and Carbapenems. The company came out with a public issue at a premium, in Nov.92, to finance its backward integration project to produce drug intermediates for semisynthetic drugs, and also to expand its antibiotic facility.Kopran has technical collaborations with Gesellschaft Fur Biotechnologische, Germany Yuhan Corporation, South Korea Ciba Corning Diagnostic, US and Adac Laboratories, US.Koprans bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Koprans high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce.The company launched new products like AZ1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, TiniNF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda.The company has been ranked as amongst the top few fastest growing companies in India(ORG MargJune 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002.The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres.The company has also increased its installed capacity of Tablets Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos).In Feb. 2001, Kopran tied up with EMerck for comarketing a new antiinflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fastmoving nonsteroid antiinflammatory drugs (NSAID),has been launched in the international market. The Company also launched Cholestat (Atorvastatin a cholesterol reducer) and further gave comarketing rights for Atorvastatin to EMerck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004.Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007. The Company during the FY 201415 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015.
Kopran Financial Highlights
Kopran reported a Q2 FY 2025-26
revenue of ₹117.91 crore,
up 0.7% YoY,
with net profit decreased
-24.4% to ₹-9.92 crore. For the full year FY2025–2026, revenue
reached ₹633.59 crore and profit touched at
₹38.55 crore.
Kopran Share Price Today
As of 18 Dec 2025, Kopran share price is ₹129.6. The stock opened at ₹130.4 and had closed at ₹130.4 the previous day. During today’s trading session, Kopran share price moved between ₹129.00 and ₹132.01, with an average price for the day of ₹130.50. Over the last 52 weeks, the stock has recorded a low of ₹123.11 and a high of ₹227.10. In terms of performance, Kopran share price has declined by 33% over the past six months and has declined by 0% over the last year.
Kopran Fundamental
Market Cap (in crs)
626.02
Face Value
10
Turnover (in lacs)
131.18
Key Metrics
Qtr Change %
42.91% Fall from 52W High
-27
Dividend yield 1yr %
High in industry
2.3
Kopran Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Kopran Quarterly Revenue
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
117.91 Cr | 137.61 Cr | 175.45 Cr | 166.24 Cr | 151.56 Cr |
Kopran Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
633.59 Cr | 629.2 Cr | 554.05 Cr | 488.13 Cr | 509.8 Cr | 360.13 Cr |
Kopran Quarterly Net Profit/Loss
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
-9.92 Cr | 7.45 Cr | 9.68 Cr | 10.4 Cr | 7.38 Cr |
Kopran Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
38.55 Cr | 50.96 Cr | 27.23 Cr | 61.03 Cr | 61.61 Cr | 21.02 Cr |
Kopran Result Highlights
Result Summary
-
Kopran Ltd reported a 14.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 22.7%.
-
Its expenses for the quarter were up by 1.3% QoQ and down 9.3% YoY.
-
The net profit decreased 233.2% QoQ and decreased 234.4% YoY.
-
The earnings per share (EPS) of Kopran Ltd declined at 2.06 during Q2 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Kopran Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
129.65
Current Price
Day EMA5
130.70
Day EMA10
132.20
Day EMA12
132.80
Day EMA20
135.70
Day EMA26
138.10
Day EMA50
146.60
Day EMA100
157.60
Day EMA200
173.70
Day SMA5
130.50
Day SMA10
132.20
Day SMA20
133.50
Day SMA30
138.50
Day SMA50
150.50
Day SMA100
159.50
Day SMA150
168.20
Day SMA200
171.90
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 63707 Rs | 104470 Rs |
Week Rs | 56013 Rs | 97595 Rs |
Month Rs | 99671 Rs | 213883 Rs |
Resistance & Support
130.22
Pivot
Resistance
First Resistance
131.44
Second Resistance
133.23
Third Resistance
134.45
Support
First Support
128.43
Second support
127.21
Third Support
125.42
Relative Strength Index
35.58
Money Flow Index
46.71
MACD
-5.36
MACD Signal
-5.90
Average True Range
5.03
Average Directional Index
26.11
Rate of Change (21)
-4.58
Rate of Change (125)
-31.94
Kopran Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
93.59 | 763.80 | 68.72 | 124 | 95.42 | -0.05% | -6.01% | -8.60% | -14.04% | 44.88% | 0.00% | 25.21 | 41.17 | 0.59 | |
331.55 | 579.58 | 293.53 | 500 | 337.05 | -1.15% | -6.92% | -25.64% | 4.39% | 114.64% | 0.00% | 18.27 | 41.17 | 1.84 | |
77.48 | 776.54 | 74.25 | 122.85 | 78.55 | -2.63% | -3.28% | -26.77% | 0.00% | 0.00% | 0.97% | 20.09 | 41.17 | 2.38 | |
395.25 | 536.07 | 292.95 | 583 | 392.95 | 1.01% | -0.30% | -3.91% | -29.88% | -54.92% | 0.24% | 61.16 | 41.17 | 1.97 | |
456.95 | 586.62 | 418.6 | 950 | 448.40 | 6.30% | -5.40% | -24.75% | -35.97% | 78.66% | 0.00% | 28.70 | 41.17 | 3.82 | |
135.68 | 721.16 | 90.78 | 172.75 | 139.46 | -4.91% | -9.61% | 0.00% | 0.00% | 0.00% | 0.00% | 35.13 | 44.36 | 3.58 |
Kopran Share Price FAQs
What is Share Price of Kopran ?
Kopran share price is ₹129.65 in NSE and ₹129.35 in BSE as on 17/12/2025.
How has Kopran shares performed in the past ?
Kopran share price in the past 1-year return was -40.76. The Kopran share hit a 1-year low of Rs. 123.11 and a 1-year high of Rs. 227.1.
What is the market cap of Kopran ?
The market cap of Kopran is Rs. 626.02 Cr. as of 17/12/2025.
What is the current P/E ratio of Kopran ?
The PE ratios of Kopran is 40.17 as of 17/12/2025.
What is the current PB ratio of Kopran ?
The PB ratios of Kopran is 1.5 as of 17/12/2025
How to buy Kopran shares?
You can easily buy Kopran shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Kopran ?
The 52-week high and low of Kopran share price is ₹227.1 and ₹123.11 as of 17/12/2025.
What is the EPS of Kopran ?
The earnings per share (EPS) of Kopran declined at 2.06 during Q2 FY 2025-26.
Please be aware that Kopran stock prices are subject to continuous fluctuations due to various factors.
Invest in Kopran